Logo

Venter's Vaccine Venture

Oct 07, 2010

Novartis has teamed up with J. Craig Venter's newly formed Synthetic Genomic Vaccines Inc. in an effort to accelerate the "production of seasonal and pandemic flu vaccines," the Wall Street Journal reports. According to Fierce Vaccines, the two firms have agreed to collaborate over a period of three years. Synthetic Genomic Vaccines and Novartis aim to "produce synthetic seed viruses, shaving as much as two months off the [standard] development timeline" of five to six months, Fierce Vaccines and the WSJ Health Blog report. Our sister publication GenomeWeb Daily News has more here.

Breaking News
The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.